Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to l-DOPA in the hemi-parkinsonian rat

Behavioural Brain Research

Volumn 270, Issue , 2014, Pages 75-85

  Ostock, Corinne Y ^a   Lindenbach, David ^a   Goldenberg, Adam A ^a   Kampton, Elias ^a   Bishop, Christopher ^a  

^a BINGHAMTON UNIVERSITY   (United States)

Author keywords

Anti DBH saporin; Dyskinesia; Locus coeruleus; Norepinephrine; Parkinson's disease

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; DOPAMINE BETA HYDROXYLASE SAPORIN; LEVODOPA; NEUROTOXIN; OXIDOPAMINE; SAPORIN; UNCLASSIFIED DRUG; DOPAMINE; DOPAMINE BETA MONOOXYGENASE; DOPAMINE RECEPTOR STIMULATING AGENT; NORADRENALIN; RIBOSOME INACTIVATING PROTEIN 1;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DENERVATION; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DYSKINESIA; IMMUNOHISTOCHEMISTRY; LOCUS CERULEUS; MALE; MEDIAL FOREBRAIN BUNDLE; MOTOR PERFORMANCE; NONHUMAN; NORADRENERGIC DENERVATION; NORADRENERGIC NERVE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; ANIMAL; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; NERVE CELL; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CORPUS STRIATUM; DENERVATION; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE BETA-HYDROXYLASE; DYSKINESIA, DRUG-INDUCED; LEVODOPA; MALE; MEDIAL FOREBRAIN BUNDLE; MOTOR ACTIVITY; NEURONS; NOREPINEPHRINE; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RIBOSOME INACTIVATING PROTEINS, TYPE 1;

EID: 84901411897     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.05.009     Document Type: Article

References (53)

1. Zarow C., Lyness S.A., Mortimer J.A., Chui H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in alzheimer and Parkinson diseases. Arch Neurol 2003, 60:5.
2. Gesi M., Soldani P., Giorgi F.S., Santinami A., Bonaccorsi I., Fornai F. The role of the locus coeruleus in the development of Parkinson's disease. Neurosci Biobehav Rev 2000, 24:4.
3. Delaville C., Deurwaerdere P.D., Noradrenaline Benazzouz A. Parkinson's disease. Front Syst Neurosci 2011, 5:31.
4. Grimbergen Y.A., Langston J.W., Roos R.A., Bloem B.R. Postural instability in Parkinson's disease: the adrenergic hypothesis and the locus coeruleus. Exp Rev Neurother 2009, 9:279-290.
5. Srinivasan J., Schmidt W.J. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease. Behav Brain Res 2004, 151:191-199.
6. Srinivasan J., Schmidt W.J. Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. Eur J Neurosc 2003, 17:2586-2592.
7. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 2005, 20(Suppl. 11):S11-S16.
8. Cenci M.A., Lundblad M. Post- versus presynaptic plasticity in l-DOPA-induced dyskinesia. J Neurochem 2006, 99:381-392.
9. Francardo V., Cenci M.A. Investigating the molecular mechanisms of l-DOPA-induced dyskinesia in the mouse. Parkinsonism Relat Disord 2014, 20(Suppl. 1):S20-S22.
10. Carta A.R., Frau L., Pinna A., Pontis S., Simola N., Schintu N., et al. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. Synapse 2008, 62:524-533.
11. Miguelez C., Aristieta A., Cenci M.A., Ugedo L. The locus coeruleus is directly implicated in l-DOPA induced dyskinesia in Parkinsonian rats: an electrophysiological and behavioural study. PLoS ONE 2011, 6:1-12.
12. Buck K., Ferger B. Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. Neuroscience 2009, 159:16-20.
13. Arai A., Tomiyama M., Kannari K., Kimura T., Suzuki C., Watanabe M., et al. Reuptake of l-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter. Synapse 2008, 62:632-635.
14. Lindenbach D., Ostock C.Y., Eskow Jaunarajs K.L., Dupre K.B., Barnum C.J., Bhide N., et al. Behavioral and cellular modulation of l-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat. J Pharmacol Exp Ther 2011, 337:755-765.
15. Barnum C.J., Bhide N., Lindenbach D., Surrena M.A., Goldenberg A.A., Tignor S., et al. Effects of noradrenergic denervation on l-DOPA-induced dyskinesia and its treatment by alpha- and beta-adrenergic receptor antagonists in hemiparkinsonian rats. Pharmacol Biochem Behav 2012, 100:607-615.
16. Rascol O., Arnulf I., Peyro-Saint Paul H., Brefel-Courbon C., Vidailhet M., Thalamas C., et al. Idazoxan, an alpha-2 antagonist, and l-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord 2001, 16:708-713.
17. Fulceri F., Biagioni F., Ferrucci M., Lazzeri G., Bartalucci A., Galli V., et al. Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons. Brain Res 2007, 1135:219-229.
18. Perez V., Marin C., Rubio A., Aguilar E., Barbanoj M., Kulisevsky J. Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances. J Neural Transm 2009, 116:1257-1266.
19. Wrenn C.C., Picklo M.J., Lappi D.A., Robertson D., Wiley R.G. Central noradrenergic lesioning using anti-DBH-saporin: anatomical findings. Brain Res 1996, 740:175-184.
20. Picklo M.J., Wiley R.G., Lappi D.A., Robertson D. Noradrenergic lesioning with an anti-dopamine beta-hydroxylase immunotoxin. Brain Res 1994, 666:195-200.
21. Barthelemy I., Martineau D., Ong M., Matsunami R., Ling N., Benatti L., et al. The expression of saporin, a ribosome-inactivating protein from the plant Saponaria officinalis, in Escherichia coli. J Biol Chem 1993, 268:6541-6548.
22. Ostock C.Y., Dupre K.B., Jaunarajs K.L., Walters H., George J., Krolewski D., et al. Role of the primary motor cortex in l-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation. Neuropharmacology 2011, 61:753-760.
23. Pisani A., Shen J. Levodopa-induced dyskinesia and striatal signaling pathways. Proc Natl Acad Sci USA 2009, 106:2973-2974.
24. Aubert I., Guigoni C., Hakansson K., Li Q., Dovero S., Barthe N., et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 2005, 57:17-26.
25. Schwarting R.K., Huston J.P. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog Neurobiol 1996, 49:215-266.
26. Tronci E., Shin E., Bjorklund A., Carta M. Amphetamine-induced rotation and l-DOPA-induced dyskinesia in the rat 6-OHDA model: a correlation study. Neurosci Res 2012, 73:168-172.
27. Dupre K.B., Eskow K.L., Barnum C.J., Bishop C. Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 2008, 55:1321-1328.
28. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, New York.
29. Gomez-Mancilla B., Bedard P.J. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys. Exp Neurol 1992, 117:185-188.
30. Rascol O., Nutt J.G., Blin O., Goetz C.G., Trugman J.M., Soubrouillard C., et al. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol 2001, 58:249-254.
31. Chondrogiorgi M., Tatsioni A., Reichmann H., Konitsiotis S. Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta-analysis of levodopa-controlled trials. Eur J Neurol 2013.
32. Lieu C.A., Subramanian T. The interhemispheric connections of the striatum: implications for Parkinson's disease and drug-induced dyskinesias. Brain Res Bull 2012, 87:1-9.
33. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970, 24:485-493.
34. Schneider M.B., Murrin L.C., Pfeiffer R.F., Deupree J.D. Dopamine receptors: effects of chronic l-dopa and bromocriptine treatment in an animal model of Parkinson's disease. Clin Neuropharmacol 1984, 7:247-257.
35. Prikhojan A., Brannan T., Yahr M.D. Comparative effects of repeated administration of dopamine agonists on circling behavior in rats. J Neural Transm 2000, 107:1159-1164.
36. Atsumi M., Kawakami J., Sugiyama E., Kotaki H., Sawada Y., Sato H., et al. Pharmacokinetic and pharmacodynamic analyses, based on dopamine D2-receptor occupancy of bromocriptine, of bromocriptine-induced contralateral rotations in unilaterally 6-OHDA-lesioned rats. Synapse 2003, 50:110-116.
37. Lane E.L., Dunnett S.B. Pre-treatment with dopamine agonists influence l-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat. Behav Brain Res 2010, 213:66-72.
38. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioral measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 2002, 15:120-132.
39. Dupre K.B., Ostock C.Y., George J.A., Eskow Jaunarajs K.L., Hueston C.M., Bishop C. Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats. ACS Chem Neurosci 2013, 4:747-760.
40. Karcz-Kubicha M., Quack G., Danysz W. Amantadine attenuates response alterations resulting from repetitive l-DOPA treatment in rats. J Neural Transm 1998, 105:1229-1236.
41. Mignon L., Wolf W.A. Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacology 2002, 163:85-94.
42. Huotari M., Kukkonen K., Liikka N., Potasev T., Raasmaja A., Mannisto P.T. Effects of histamine H(3)-ligands on the levodopa-induced turning behavior of hemiparkinsonian rats. Parkinsonism Relat Disord 2000, 6:159-164.
43. Chang J.W., Wachtel S.R., Young D., Kang U.J. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 1999, 88:617-628.
44. Archer T., Fredriksson A. Influence of noradrenaline denervation on MPTP-induced deficits in mice. J Neural Transm 2006, 113:1119-1129.
45. Nishi K., Kondo T., Narabayashi H. Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by l-dopa. Neurosci Lett 1991, 123:244-247.
46. Alachkar A., Brotchie J.M., Jones O.T. Binding of dopamine and 3-methoxytyramine as l-DOPA metabolites to human alpha(2)-adrenergic and dopaminergic receptors. Neurosci Res 2010, 67:245-249.
47. Anden N., Grabowska M. Pharmacological evidence for a stimulation of dopamine neurons by noradrenaline neurons in the brain. Eur J Pharmacol 1976, 39:275-282.
48. Sallinen J., Link R.E., Haapalinna A., Viitamaa T., Kulatunga M., Sjoholm B., et al. Genetic alteration of alpha 2C-adrenoceptor expression in mice: influence on locomotor, hypothermic, and neurochemical effects of dexmedetomidine, a subtype-nonselective alpha 2-adrenoceptor agonist. Mol Pharmacol 1997, 51:36-46.
49. Carpentier A.F., Bonnet A.M., Vidailhet M., Agid Y. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology 1996, 46:1548-1551.
50. Henry B., Fox S.H., Peggs D., Crossman A.R., Brotchie J.M. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of l-DOPA in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 1999, 14:744-753.
51. Lewitt P.A. Norepinephrine: the next therapeutics frontier for Parkinson's disease. Transl Neurodegener 2012, 1:4.
52. German D.C., Manaye K.F., White C.L., Woodward D.J., McIntire D.D., Smith W.K., et al. Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 1992, 32:10.
53. Rommelfanger K.S., Edwards G.L., Freeman K.G., Liles L.C., Miller G.W., Weinshenker D. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc Natl Acad Sci USA 2007, 104:13804-13809.